Initiation - Spark Newswire

1 minute read

JP Morgan Initiates Coverage On Convey Holding Parent with Neutral Rating, Announces Price Target of $12

Today, 9:20 AM

JP Morgan analyst Anne Samuel initiates coverage on Convey Holding Parent (NYSE:CNVY) with a Neutral rating and announces Price Target of $12.

CNVY

1 minute read

JP Morgan Initiates Coverage On Lyell Immunopharma with Overweight Rating, Announces Price Target of $22

By Benzinga Newsdesk

Today, 9:20 AM

JP Morgan initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Overweight rating and announces Price Target of $22.

LYEL

1 minute read

Jefferies Initiates Coverage On Verve Therapeutics with Buy Rating

By Benzinga Newsdesk

Today, 9:20 AM

Jefferies analyst Eun Yang initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Buy rating.

VERV

1 minute read

Berenberg Initiates Coverage On Medigene with Buy Rating

By Benzinga Newsdesk

Today, 9:20 AM

Berenberg initiates coverage on Medigene (OTC:MDGEF) with a Buy rating.

MDGEF

1 minute read

Citigroup Initiates Coverage On ATI Physical Therapy with Buy Rating, Announces Price Target of $11

By Benzinga Newsdesk

Today, 9:20 AM

Citigroup initiates coverage on ATI Physical Therapy (NYSE:ATIP) with a Buy rating and announces Price Target of $11.

ATIP

1 minute read

Piper Sandler Initiates Coverage On TriplePoint Venture Gwth with Overweight Rating, Announces Price Target of $17

By Benzinga Newsdesk

Today, 9:20 AM

Piper Sandler analyst Crispin Love initiates coverage on TriplePoint Venture Gwth (NYSE:TPVG) with a Overweight rating and announces Price Target of $17.

TPVG

1 minute read

Goldman Sachs Initiates Coverage On WalkMe with Buy Rating, Announces Price Target of $47

By Benzinga Newsdesk

Today, 9:20 AM

Goldman Sachs analyst Christopher Merwin initiates coverage on WalkMe (NASDAQ:WKME) with a Buy rating and announces Price Target of $47.

WKME

1 minute read

Piper Sandler Initiates Coverage On Solid Biosciences with Neutral Rating, Announces Price Target of $6

By Benzinga Newsdesk

Today, 9:20 AM

Piper Sandler analyst Christopher Raymond initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Neutral rating and announces Price Target of $6.

SLDB